3S3I
p38 kinase crystal structure in complex with small molecule inhibitor
Summary for 3S3I
| Entry DOI | 10.2210/pdb3s3i/pdb |
| Descriptor | Mitogen-activated protein kinase 14, 3-(3-tert-butyl[1,2,4]triazolo[4,3-a]pyridin-7-yl)-N-cyclopropyl-4-methylbenzamide (3 entities in total) |
| Functional Keywords | p38 map kinase, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| Biological source | Homo sapiens (human) |
| Cellular location | Cytoplasm: Q16539 |
| Total number of polymer chains | 1 |
| Total formula weight | 40383.25 |
| Authors | Segarra, V.,Aiguade, J.,Roca, R.,Fisher, M.,Lamers, M. (deposition date: 2011-05-18, release date: 2012-04-04, Last modification date: 2023-09-13) |
| Primary citation | Aiguade, J.,Balague, C.,Carranco, I.,Caturla, F.,Dominguez, M.,Eastwood, P.,Esteve, C.,Gonzalez, J.,Lumeras, W.,Orellana, A.,Preciado, S.,Roca, R.,Vidal, L.,Vidal, B. Novel triazolopyridylbenzamides as potent and selective p38 alpha inhibitors. Bioorg.Med.Chem.Lett., 22:3431-3436, 2012 Cited by PubMed Abstract: A new class of p38α inhibitors based on a biaryl-triazolopyridine scaffold was investigated. X-ray crystallographic data of the initial lead compound cocrystallised with p38α was crucial in order to uncover a unique binding mode of the inhibitor to the hinge region via a pair of water molecules. Synthesis and SAR was directed towards the improvement of binding affinity, as well as ADME properties for this new class of p38α inhibitors and ultimately afforded compounds showing good in vivo efficacy. PubMed: 22521646DOI: 10.1016/j.bmcl.2012.03.099 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.8 Å) |
Structure validation
Download full validation report






